SEC Form 4 · accession 0001193125-26-303188
CG Oncology, Inc. · CGON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James Mulay
Director
Period of report
Jul 10, 2026
Accepted (ET)
Jul 14, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001991792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 10, 2026 | M | 24,165 | $26.63 | A | 24,165 | D | |
| Common StockF2 | Jul 10, 2026 | S | 24,165 | $75.16 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy)F3 | $26.63 | Jul 10, 2026 | M | 24,165 | D | — | Jun 4, 2035 | Common Stock | 24,165 | 0 | D |
Explanation of responses
- F1The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Fully vested.